Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection.

Elliott, A M; Foster, S D

Elliott, A M; Foster, S D.

Affiliation

Elliott AM; Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA.

Tuber Lung Dis ; 77(1): 27-9, 1996 Feb.

Article in En | MEDLINE | ID: mdl-8733410

Subject(s)

AIDS-Related Opportunistic Infections/drug therapy; Antitubercular Agents/adverse effects; Drug Eruptions/etiology; Thioacetazone/adverse effects; Tuberculosis/drug therapy; Antitubercular Agents/economics; Antitubercular Agents/therapeutic use; Humans; Thioacetazone/economics; Thioacetazone/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thioacetazone / Tuberculosis / AIDS-Related Opportunistic Infections / Drug Eruptions / Antitubercular Agents Type of study: Prevalence_studies / Risk_factors_studies Limits: Humans Language: En Journal: Tuber Lung Dis Year: 1996 Document type: Article Affiliation country: United States Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links